Showing 5431-5440 of 5771 results for "".
- OWL to Host Signature Event and Awards Ceremony at AAO 2018https://modernod.com/news/owl-to-host-signature-event-and-awards-ceremony-at-aao-2018/2479767/OWL: Advancing Diversity in Leadership (OWL) announced that it will host its annual OWL Signature Event and Awards Ceremony at the American Academy of Ophthalmology (AAO). OWL’s largest event of the year will take place on Sunday, October 28, 2018 from 5:30-7:00 p.m., at Revel Motor Row in Chicag
- Allergan to Present New Data on Investigational Medicines at AAOhttps://modernod.com/news/allergan-to-present-new-data-on-investigational-medicines-at-aao/2479768/Allergan will present new data at the annual meeting of the American College of Ophthalmology (AAO) to be held in Chicago. The Retina Subspecialty Day (October 26-27) will feature two late-breaker presentations on the
- LEH Pharma Appoints Syneos Health as Global Clinical Development and Commercialization Solutions Providerhttps://modernod.com/news/leh-pharma-appoints-syneos-health-as-global-clinical-development-and-commercialization-solutions-provider/2479769/LEH Pharma, a provider of ocular implants for macular disorders, announced the selection of Syneos Health, a fully integrated biopharmaceutical solutions organization, as its global clinical development and commercialization provider. The primary aim of the strategic relationship is to acc
- Oxurion Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Projecthttps://modernod.com/news/oxurion-extends-partnership-with-retina-global-in-support-of-bolivian-diabetic-retinopathy-boldr-project/2479770/Oxurion NV announced it is extending its partnership with Retina Global, an international nonprofit organization focused on sustainable outcomes to retinal disease management in underserved areas around the world. Oxurion will support Retina Global’s Bolivian Diabetic Retinopathy Project (BOLDR),
- Hoya Surgical Optics to Acquire Ophthalmic Medical Device Companies Mid Labs, Fritz Ruckhttps://modernod.com/news/hoya-surgical-optics-to-acquire-ophthalmic-medical-device-companies-mid-labs-fritz-ruck/2479775/Hoya Surgical Optics announced that it has entered into a definitive agreement to acquire two medical device companies: US-based Mid Labs and Germany-based Fritz Ruck. Mid Labs is a California-based company focused on the research, innovation, development, engineering, and manufacturin
- I-MED Pharma Partners With Quidel to Introduce I-Lid ’N Lash, I-Relief, and SMTube to the US Markethttps://modernod.com/news/i-med-pharma-partners-with-quidel-to-introduce-i-lid-n-lash-i-relief-and-smtube-to-the-us-market/2479777/I-MED Pharma, a company specializing in dry eye diagnosis and management, announced the signing of an exclusive distribution agreement with Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems, for I-MED Pha
- US Proposes Rule Requiring Drugmakers to Disclose List Prices of Drugs in DTC Advertisinghttps://modernod.com/news/us-proposes-rule-requiring-drugmakers-to-disclose-list-prices-of-drugs-in-dtc-advertising/2479780/US Health and Human Services Secretary Alex Azar announced a proposed rule change that would require pharmaceutical companies to provide the list prices of certain drugs in direct-to-consumer (DTC) advertising. Specifically, the proposal will require drugmakers to disclose in DTC television adver
- ImprimisRx to Feature New Formulation and Poster Presentation on MKO Melt at AAO Meeting in Chicagohttps://modernod.com/news/imprimisrx-to-feature-new-formulation-and-poster-presentation-on-mko-melt-at-aao-meeting-in-chicago/2479781/ImprimisRx announced its participation at the upcoming 2018 American Academy of Ophthalmology (AAO) annual meeting to be held at the McCormick Place Convention Center in Chicago, October 26-30. At the conference, attendees will have the opportunity to meet with ImprimisRx representatives
- Kala Pharmaceuticals Submits NDA to FDA for KPI-121 0.25% for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-submits-nda-to-fda-for-kpi-121-0-25-for-dry-eye-disease/2479782/Kala Pharmaceuticals announced that it has submitted a new drug application (NDA) to the FDA for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. There are an estimated
- Altris.AI Partners With Huvitz for Development of AI-Based Retinal Detectionhttps://modernod.com/news/altris-ai-the-new-era-of-retinal-diagnosis-is-coming/2479785/Artificial intelligence company Altris.Al announced it has signed an agreement with South Korean ophthalmic and optical medical equipment manufacturer Huvitz Co. aimed at the development of customized deep learning solutions for retinal diseases detection. Terms of the deal were not disclo